# Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931)

> **NCT00451100** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 84 (actual)

## Conditions studied

- Anesthesia, General

## Interventions

- **DRUG:** Sugammadex
- **DRUG:** neostigmine

## Key facts

- **NCT ID:** NCT00451100
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11-10
- **Primary completion:** 2006-05-22
- **Final completion:** 2006-08-29
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2019-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00451100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00451100, "Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00451100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*